Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors

Igor A. Schepetkin, Liliya N. Kirpotina, Andrey Ivanovich Khlebnikov, Tracey S. Hanks, Irina Kochetkova, David W. Pascual, Mark A. Jutila, Mark T. Quinn

Результат исследований: Материалы для журналаСтатья

25 Цитирования (Scopus)

Выдержка

In efforts to identify novel small molecules with anti-inflammatory properties, we discovered a unique series of tetracyclic indenoquinoxaline derivatives that inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 activation. Compound IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was found to be a potent, noncytotoxic inhibitor of pro-inflammatory cytokine [interleukin (IL)-1α, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon-γ, and granulocyte-macrophage colony-stimulating factor] and nitric oxide production by human and murine monocyte/macrophages. Three additional potent inhibitors of cytokine production were identified through further screening of IQ-1 analogs. The sodium salt of IQ-1 inhibited LPS-induced TNF-α and IL-6 production in MonoMac-6 cells with IC 50 values of 0.25 and 0.61 μM, respectively. Screening of 131 protein kinases revealed that derivative IQ-3 [11H-indeno[1,2-b]quinoxalin-11-one-O-(2-furoyl)oxime]was a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. This compound, as well as IQ-1 and three additional oxime indenoquinoxalines, were found to be high-affinity JNK inhibitors with nanomolar binding affinity and ability to inhibit c-Jun phosphorylation. Furthermore, docking studies showed that hydrogen bonding interactions of the active indenoquinoxalines with Asn152, Gln155, and Met149 of JNK3 played an important role in enzyme binding activity. Finally, we showed that the sodium salt of IQ-1 had favorable pharmacokinetics and inhibited the ovalbumin-induced CD4 + T-cell immune response in a murine delayed-type hypersensitivity model in vivo. We conclude that compounds with an indenoquinoxaline nucleus can serve as specific small-molecule modulators for mechanistic studies of JNKs as well as a potential leads for the development of anti-inflammatory drugs.

Язык оригиналаАнглийский
Страницы (с-по)832-845
Число страниц14
ЖурналMolecular Pharmacology
Том81
Номер выпуска6
DOI
СостояниеОпубликовано - июн 2012
Опубликовано для внешнего пользованияДа

Отпечаток

Oximes
JNK Mitogen-Activated Protein Kinases
Interleukin-1
Lipopolysaccharides
Interleukin-6
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Salts
Sodium
Cytokines
Quinoxalines
Ovalbumin
Delayed Hypersensitivity
Hydrogen Bonding
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-10
Protein Kinases
Interferons
Monocytes
Nitric Oxide

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Цитировать

Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. / Schepetkin, Igor A.; Kirpotina, Liliya N.; Khlebnikov, Andrey Ivanovich; Hanks, Tracey S.; Kochetkova, Irina; Pascual, David W.; Jutila, Mark A.; Quinn, Mark T.

В: Molecular Pharmacology, Том 81, № 6, 06.2012, стр. 832-845.

Результат исследований: Материалы для журналаСтатья

Schepetkin, IA, Kirpotina, LN, Khlebnikov, AI, Hanks, TS, Kochetkova, I, Pascual, DW, Jutila, MA & Quinn, MT 2012, 'Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors', Molecular Pharmacology, том. 81, № 6, стр. 832-845. https://doi.org/10.1124/mol.111.077446
Schepetkin, Igor A. ; Kirpotina, Liliya N. ; Khlebnikov, Andrey Ivanovich ; Hanks, Tracey S. ; Kochetkova, Irina ; Pascual, David W. ; Jutila, Mark A. ; Quinn, Mark T. / Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. В: Molecular Pharmacology. 2012 ; Том 81, № 6. стр. 832-845.
@article{c0c75ea9153f4be9b71ae53d530c389a,
title = "Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors",
abstract = "In efforts to identify novel small molecules with anti-inflammatory properties, we discovered a unique series of tetracyclic indenoquinoxaline derivatives that inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 activation. Compound IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was found to be a potent, noncytotoxic inhibitor of pro-inflammatory cytokine [interleukin (IL)-1α, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon-γ, and granulocyte-macrophage colony-stimulating factor] and nitric oxide production by human and murine monocyte/macrophages. Three additional potent inhibitors of cytokine production were identified through further screening of IQ-1 analogs. The sodium salt of IQ-1 inhibited LPS-induced TNF-α and IL-6 production in MonoMac-6 cells with IC 50 values of 0.25 and 0.61 μM, respectively. Screening of 131 protein kinases revealed that derivative IQ-3 [11H-indeno[1,2-b]quinoxalin-11-one-O-(2-furoyl)oxime]was a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. This compound, as well as IQ-1 and three additional oxime indenoquinoxalines, were found to be high-affinity JNK inhibitors with nanomolar binding affinity and ability to inhibit c-Jun phosphorylation. Furthermore, docking studies showed that hydrogen bonding interactions of the active indenoquinoxalines with Asn152, Gln155, and Met149 of JNK3 played an important role in enzyme binding activity. Finally, we showed that the sodium salt of IQ-1 had favorable pharmacokinetics and inhibited the ovalbumin-induced CD4 + T-cell immune response in a murine delayed-type hypersensitivity model in vivo. We conclude that compounds with an indenoquinoxaline nucleus can serve as specific small-molecule modulators for mechanistic studies of JNKs as well as a potential leads for the development of anti-inflammatory drugs.",
author = "Schepetkin, {Igor A.} and Kirpotina, {Liliya N.} and Khlebnikov, {Andrey Ivanovich} and Hanks, {Tracey S.} and Irina Kochetkova and Pascual, {David W.} and Jutila, {Mark A.} and Quinn, {Mark T.}",
year = "2012",
month = "6",
doi = "10.1124/mol.111.077446",
language = "English",
volume = "81",
pages = "832--845",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors

AU - Schepetkin, Igor A.

AU - Kirpotina, Liliya N.

AU - Khlebnikov, Andrey Ivanovich

AU - Hanks, Tracey S.

AU - Kochetkova, Irina

AU - Pascual, David W.

AU - Jutila, Mark A.

AU - Quinn, Mark T.

PY - 2012/6

Y1 - 2012/6

N2 - In efforts to identify novel small molecules with anti-inflammatory properties, we discovered a unique series of tetracyclic indenoquinoxaline derivatives that inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 activation. Compound IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was found to be a potent, noncytotoxic inhibitor of pro-inflammatory cytokine [interleukin (IL)-1α, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon-γ, and granulocyte-macrophage colony-stimulating factor] and nitric oxide production by human and murine monocyte/macrophages. Three additional potent inhibitors of cytokine production were identified through further screening of IQ-1 analogs. The sodium salt of IQ-1 inhibited LPS-induced TNF-α and IL-6 production in MonoMac-6 cells with IC 50 values of 0.25 and 0.61 μM, respectively. Screening of 131 protein kinases revealed that derivative IQ-3 [11H-indeno[1,2-b]quinoxalin-11-one-O-(2-furoyl)oxime]was a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. This compound, as well as IQ-1 and three additional oxime indenoquinoxalines, were found to be high-affinity JNK inhibitors with nanomolar binding affinity and ability to inhibit c-Jun phosphorylation. Furthermore, docking studies showed that hydrogen bonding interactions of the active indenoquinoxalines with Asn152, Gln155, and Met149 of JNK3 played an important role in enzyme binding activity. Finally, we showed that the sodium salt of IQ-1 had favorable pharmacokinetics and inhibited the ovalbumin-induced CD4 + T-cell immune response in a murine delayed-type hypersensitivity model in vivo. We conclude that compounds with an indenoquinoxaline nucleus can serve as specific small-molecule modulators for mechanistic studies of JNKs as well as a potential leads for the development of anti-inflammatory drugs.

AB - In efforts to identify novel small molecules with anti-inflammatory properties, we discovered a unique series of tetracyclic indenoquinoxaline derivatives that inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 activation. Compound IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was found to be a potent, noncytotoxic inhibitor of pro-inflammatory cytokine [interleukin (IL)-1α, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon-γ, and granulocyte-macrophage colony-stimulating factor] and nitric oxide production by human and murine monocyte/macrophages. Three additional potent inhibitors of cytokine production were identified through further screening of IQ-1 analogs. The sodium salt of IQ-1 inhibited LPS-induced TNF-α and IL-6 production in MonoMac-6 cells with IC 50 values of 0.25 and 0.61 μM, respectively. Screening of 131 protein kinases revealed that derivative IQ-3 [11H-indeno[1,2-b]quinoxalin-11-one-O-(2-furoyl)oxime]was a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. This compound, as well as IQ-1 and three additional oxime indenoquinoxalines, were found to be high-affinity JNK inhibitors with nanomolar binding affinity and ability to inhibit c-Jun phosphorylation. Furthermore, docking studies showed that hydrogen bonding interactions of the active indenoquinoxalines with Asn152, Gln155, and Met149 of JNK3 played an important role in enzyme binding activity. Finally, we showed that the sodium salt of IQ-1 had favorable pharmacokinetics and inhibited the ovalbumin-induced CD4 + T-cell immune response in a murine delayed-type hypersensitivity model in vivo. We conclude that compounds with an indenoquinoxaline nucleus can serve as specific small-molecule modulators for mechanistic studies of JNKs as well as a potential leads for the development of anti-inflammatory drugs.

UR - http://www.scopus.com/inward/record.url?scp=84861437451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861437451&partnerID=8YFLogxK

U2 - 10.1124/mol.111.077446

DO - 10.1124/mol.111.077446

M3 - Article

C2 - 22434859

AN - SCOPUS:84861437451

VL - 81

SP - 832

EP - 845

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -